Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine as adjunctive therapy for mild to moderate COVID-19
IRCT20200408046990N2Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Apr 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of colchicine in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Treatment response rate and Adverse drug reactions. Started Apr 2020; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20200408046990N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200408046990N2.